Home > Healthcare > Biotechnology > Biotechnology R&D > Human Microbiome Market

Human Microbiome Market Share

Report ID: GMI6538
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Human Microbiome Market Share

These companies are at the forefront of developing microbiome-based drugs and therapies, focusing on addressing unmet medical needs in areas such as infectious diseases, gastrointestinal disorders, and metabolic conditions. Strategic partnerships, collaborations with academic institutions, and investments in research and development are key strategies employed by industry leaders to enhance their market presence and accelerate the commercialization of microbiome-based therapies.

Human Microbiome Market Companies

The competitive landscape of the human microbiome industry includes 4D Pharma plc.

Synlogic
Microbiome Therapeutics LLC
Enterome
Metabiomics Corporation
Seres Therapeutics
Second Genome Inc.
Vedanta Biosciences, Inc.
Synthetic Biologics, Inc.
DuPont

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global human microbiome industry was valued at USD 842.4 million in 2023 and is expected to grow at a CAGR of 25.7% from 2024 to 2032, driven by increasing interest in the role of microbiota in health and disease.

The digestive tract segment dominated the market with a 31.7% share in 2023 due to the gut microbiomes critical role in digestion, immunity, and overall health, making it a primary target for microbiome-based therapeutics.

The North America human microbiome market reached USD 261.2 million in 2023 and is expected to demonstrate a 24.9% CAGR through 2032, attributed to the presence of major pharmaceutical companies, extensive research infrastructure, and growing investment in microbiome-based therapeutics.

Key players in the industry include 4D Pharma plc, Synlogic, Microbiome Therapeutics LLC, Enterome, Metabiomics Corporation, Seres Therapeutics, Second Genome Inc., Vedanta Biosciences, Inc., Synthetic Biologics, Inc., and DuPont.